{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Ewing+Sarcoma%2FPeripheral+Primitive+Neuroectodermal+Tumor",
    "query": {
      "condition": "Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 89,
    "total_pages": 9,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Ewing+Sarcoma%2FPeripheral+Primitive+Neuroectodermal+Tumor&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-21T20:39:24.547Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04320888",
      "title": "Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hematopoietic and Lymphatic System Neoplasm",
        "Recurrent Ependymoma",
        "Recurrent Ewing Sarcoma",
        "Recurrent Hepatoblastoma",
        "Recurrent Histiocytic and Dendritic Cell Neoplasm",
        "Recurrent Langerhans Cell Histiocytosis",
        "Recurrent Lymphoma",
        "Recurrent Malignant Germ Cell Tumor",
        "Recurrent Malignant Glioma",
        "Recurrent Malignant Solid Neoplasm",
        "Recurrent Medulloblastoma",
        "Recurrent Neuroblastoma",
        "Recurrent Non-Hodgkin Lymphoma",
        "Recurrent Osteosarcoma",
        "Recurrent Peripheral Primitive Neuroectodermal Tumor",
        "Recurrent Rhabdoid Tumor",
        "Recurrent Rhabdomyosarcoma",
        "Recurrent Soft Tissue Sarcoma",
        "Recurrent WHO Grade 2 Glioma",
        "Refractory Ependymoma",
        "Refractory Ewing Sarcoma",
        "Refractory Hepatoblastoma",
        "Refractory Histiocytic and Dendritic Cell Neoplasm",
        "Refractory Langerhans Cell Histiocytosis",
        "Refractory Lymphoma",
        "Refractory Malignant Germ Cell Tumor",
        "Refractory Malignant Glioma",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Medulloblastoma",
        "Refractory Neuroblastoma",
        "Refractory Non-Hodgkin Lymphoma",
        "Refractory Osteosarcoma",
        "Refractory Peripheral Primitive Neuroectodermal Tumor",
        "Refractory Rhabdoid Tumor",
        "Refractory Rhabdomyosarcoma",
        "Refractory Soft Tissue Sarcoma",
        "Refractory WHO Grade 2 Glioma",
        "Wilms Tumor"
      ],
      "interventions": [
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Radionuclide Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Selpercatinib",
          "type": "DRUG"
        },
        {
          "name": "X-Ray Imaging",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "12 Months to 21 Years"
      },
      "enrollment_count": 1,
      "start_date": "2021-05-03",
      "completion_date": "2026-06-30",
      "has_results": true,
      "last_update_posted_date": "2026-05-04",
      "last_synced_at": "2026-05-21T20:39:24.547Z",
      "location_count": 172,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04320888"
    },
    {
      "nct_id": "NCT02076906",
      "title": "MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Relapsed Pediatric Solid Tumors",
        "Refractory Pediatric Solid Tumors",
        "Rhabdomyosarcoma",
        "Ewing Sarcoma",
        "Osteosarcoma",
        "Neuroblastoma",
        "Wilms Tumor",
        "Hepatic Tumor",
        "Germ Cell Tumor",
        "Desmoid Tumor"
      ],
      "interventions": [
        {
          "name": "Magnetic Resonance High Intensity Focused Ultrasound",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "AeRang Kim",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "Up to 30 Years"
      },
      "enrollment_count": 7,
      "start_date": "2014-04",
      "completion_date": "2024-11-24",
      "has_results": false,
      "last_update_posted_date": "2025-01-01",
      "last_synced_at": "2026-05-21T20:39:24.547Z",
      "location_count": 2,
      "location_summary": "Washington D.C., District of Columbia • Cincinnati, Ohio",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02076906"
    },
    {
      "nct_id": "NCT02748135",
      "title": "A Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Relapsed or Refractory Medulloblastoma (MB), Neuroblastoma (NB), Ewing Sarcoma (ES) and Alveolar Rhabdomyosarcoma (ARMS)"
      ],
      "interventions": [
        {
          "name": "TB-403 20mg/kg",
          "type": "DRUG"
        },
        {
          "name": "TB-403 50mg/kg",
          "type": "DRUG"
        },
        {
          "name": "TB-403 100mg/kg",
          "type": "DRUG"
        },
        {
          "name": "TB-403 175mg/kg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oncurious NV",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "6 Months to 18 Years"
      },
      "enrollment_count": 18,
      "start_date": "2016-05",
      "completion_date": "2020-10-06",
      "has_results": false,
      "last_update_posted_date": "2021-01-13",
      "last_synced_at": "2026-05-21T20:39:24.547Z",
      "location_count": 10,
      "location_summary": "Little Rock, Arkansas • Oakland, California • Hartford, Connecticut + 7 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02748135"
    },
    {
      "nct_id": "NCT02982941",
      "title": "Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neuroblastoma",
        "Rhabdomyosarcoma",
        "Osteosarcoma",
        "Ewing Sarcoma",
        "Wilms Tumor",
        "Desmoplastic Small Round Cell Tumor"
      ],
      "interventions": [
        {
          "name": "Enoblituzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MacroGenics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "1 Year to 35 Years"
      },
      "enrollment_count": 25,
      "start_date": "2016-12",
      "completion_date": "2019-05-22",
      "has_results": false,
      "last_update_posted_date": "2022-02-08",
      "last_synced_at": "2026-05-21T20:39:24.547Z",
      "location_count": 6,
      "location_summary": "Palo Alto, California • Bethesda, Maryland • Philadelphia, Pennsylvania + 3 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02982941"
    },
    {
      "nct_id": "NCT02574728",
      "title": "Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "Celecoxib",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "12 Months to 30 Years"
      },
      "enrollment_count": 46,
      "start_date": "2015-06",
      "completion_date": "2026-06",
      "has_results": false,
      "last_update_posted_date": "2026-03-02",
      "last_synced_at": "2026-05-21T20:39:24.547Z",
      "location_count": 6,
      "location_summary": "Phoenix, Arizona • Wilmington, Delaware • Atlanta, Georgia + 2 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Wilmington",
          "state": "Delaware"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02574728"
    },
    {
      "nct_id": "NCT00516295",
      "title": "Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ewing Sarcoma of Bone",
        "Extraosseous Ewing Sarcoma",
        "Peripheral Primitive Neuroectodermal Tumor",
        "Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor"
      ],
      "interventions": [
        {
          "name": "topotecan hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "vincristine sulfate",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "bevacizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "29 Years",
        "sex": "ALL",
        "summary": "1 Year to 29 Years"
      },
      "enrollment_count": 7,
      "start_date": "2008-02",
      "completion_date": "2010-01",
      "has_results": true,
      "last_update_posted_date": "2014-09-02",
      "last_synced_at": "2026-05-21T20:39:24.547Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00516295"
    },
    {
      "nct_id": "NCT00470275",
      "title": "Cytarabine in Treating Young Patients With Recurrent or Refractory Ewing's Sarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "cytarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "Up to 30 Years"
      },
      "enrollment_count": 10,
      "start_date": "2007-05",
      "completion_date": "2013-12",
      "has_results": true,
      "last_update_posted_date": "2014-10-20",
      "last_synced_at": "2026-05-21T20:39:24.547Z",
      "location_count": 63,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 56 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Madera",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00470275"
    },
    {
      "nct_id": "NCT00070109",
      "title": "Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Previously Treated Childhood Rhabdomyosarcoma",
        "Recurrent Childhood Rhabdomyosarcoma",
        "Recurrent Childhood Soft Tissue Sarcoma",
        "Recurrent Ewing Sarcoma",
        "Peripheral Primitive Neuroectodermal Tumor"
      ],
      "interventions": [
        {
          "name": "trabectedin",
          "type": "DRUG"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "12 Months to 50 Years"
      },
      "enrollment_count": 50,
      "start_date": "2008-01",
      "completion_date": "2013-12",
      "has_results": true,
      "last_update_posted_date": "2018-09-14",
      "last_synced_at": "2026-05-21T20:39:24.547Z",
      "location_count": 11,
      "location_summary": "Little Rock, Arkansas • Madera, California • Chicago, Illinois + 7 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Madera",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00070109"
    },
    {
      "nct_id": "NCT00030667",
      "title": "Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Childhood Desmoplastic Small Round Cell Tumor",
        "Childhood Synovial Sarcoma",
        "Gastrointestinal Stromal Tumor",
        "Lung Metastases",
        "Recurrent Childhood Soft Tissue Sarcoma",
        "Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor",
        "Recurrent Neuroblastoma",
        "Recurrent Osteosarcoma"
      ],
      "interventions": [
        {
          "name": "imatinib mesylate",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "Up to 30 Years"
      },
      "enrollment_count": 100,
      "start_date": "2002-05",
      "completion_date": "2005-12",
      "has_results": false,
      "last_update_posted_date": "2015-04-15",
      "last_synced_at": "2026-05-21T20:39:24.547Z",
      "location_count": 1,
      "location_summary": "Arcadia, California",
      "locations": [
        {
          "city": "Arcadia",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00030667"
    },
    {
      "nct_id": "NCT04530487",
      "title": "Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Desmoplastic Small Round Cell Tumor",
        "Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor",
        "Recurrent Desmoplastic Small Round Cell Tumor",
        "Recurrent Malignant Peripheral Nerve Sheath Tumor",
        "Recurrent Malignant Solid Neoplasm",
        "Recurrent Neuroblastoma",
        "Recurrent Rhabdomyosarcoma",
        "Refractory Desmoplastic Small Round Cell Tumor",
        "Refractory Malignant Peripheral Nerve Sheath Tumor",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Neuroblastoma",
        "Refractory Rhabdomyosarcoma"
      ],
      "interventions": [
        {
          "name": "Allogeneic Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Lapine T-Lymphocyte Immune Globulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Thiotepa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "Up to 25 Years"
      },
      "enrollment_count": 1,
      "start_date": "2020-08-19",
      "completion_date": "2024-08-26",
      "has_results": true,
      "last_update_posted_date": "2025-06-29",
      "last_synced_at": "2026-05-21T20:39:24.547Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04530487"
    }
  ]
}